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Abstract
It has been hypothesised that the perception of adverse events in placebo-controlled antide-
pressant clinical trials may induce patients to conclude that they have been randomized to
the active arm of the trial, leading to the breaking of blind. This may enhance the expectan-
cies for improvement and the therapeutic response. The main objective of this study is to
test the hypothesis that the efficacy of antidepressants in panic disorder is mediated by the
perception of adverse events. The present analysis is based on a systematic review of pub-
lished and unpublished randomised trials comparing antidepressants with placebo for panic
disorder. The Baron and Kenny approach was applied to investigate the mediational role of
adverse events in the relationship between antidepressants treatment and efficacy. Four-
teen placebo-controlled antidepressants trials were included in the analysis. We found that:
(a) antidepressants treatment was significantly associated with better treatment response
(ß = 0.127, 95% CI 0.04 to 0.21, p = 0.003); (b) antidepressants treatment was not associ-
ated with adverse events (ß = 0.094, 95% CI -0.05 to 0.24, p = 0.221); (c) adverse events
were negatively associated with treatment response (ß = 0.035, 95% CI -0.06 to -0.05, p =
0.022). Finally, after adjustment for adverse events, the relationship between antidepres-
sants treatment and treatment response remained statistically significant (ß = 0.122, 95%
CI 0.01 to 0.23, p = 0.039). These findings do not support the hypothesis that the perception
of adverse events in placebo-controlled antidepressant clinical trials may lead to the break-
ing of blind and to an artificial inflation of the efficacy measures. Based on these results, we
argue that the moderate therapeutic effect of antidepressants in individuals with panic disor-
der is not an artefact, therefore reflecting a genuine effect that doctors can expect to repli-
cate under real-world conditions.
Introduction
In randomised studies allocating patients to antidepressants or placebo it is possible that differ-
ences in efficacy may, at least in part, be explained by the emergence of adverse events. In the
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treatment of major depression the evidence is controversial. A meta-analysis of studies com-
paring fluoxetine with placebo reported a strong correlation between adverse events and effi-
cacy, and authors supposed that the rating scores for patients allocated to antidepressants
might have been amplified when study participants became aware of being allocated to active
treatment by experiencing adverse events [1]. A more recent study on antidepressants in
depression, however, was not able to replicate this finding [2].
A similar hypothesis may be formulated for antidepressants in the treatment of panic disor-
der, as patients with panic disorder may be particularly prone to adverse events and these, in
turn, may have an impact on efficacy measures. The hypothesis is the following. During the
informed consent procedure, patients with panic disorder are told that they may receive pla-
cebo and are also informed of the side effects to be expected from the real drug. Hence, when
they experience side effects, they are likely to conclude that they have been randomized to the
active arm of the trial. In fact, most patients and doctors in clinical trials are successfully able
to guess whether the patient has been randomized to drug or placebo ([3]; [4]; [5]; [6]). Since
the placebo effect is presumed to be associated with expectancies for improvement, concluding
that one has been given the real drug (after experiencing adverse events) ought to enhance the
therapeutic response, whereas concluding that one has been given placebo (after not
experiencing adverse events) ought to diminish it.
If drug-placebo differences are due to the breaking of blind, then they ought to be associ-
ated with the perception of adverse events. The purpose of the study reported here is to test the
hypothesis that the effects of antidepressants are correlated with the perception of adverse
events and to assess what remains of the drug effect when side effects are controlled statisti-
cally. We were able to test this hypothesis performing a mediational analysis.
Materials and methods
Search methods for identification of studies
The present study is based on an ongoing Cochrane systematic review and meta-analysis of
published and unpublished randomised trials comparing antidepressants versus placebo for
panic disorder [7]. We refer to Guaiana et al. for a detailed description of the search strategy
and full methodology. Briefly, the Cochrane Collaboration Common Mental Disorder Group
Trials Register (CCDANTR) was searched. This register includes relevant RCTs from the
Cochrane Central Register of Controlled Trials (CENTRAL) (all years), MEDLINE (1950 to
date), EMBASE (1974 to date) and PsycINFO (1967 to date). No language restriction was
applied. Reference lists of relevant papers and previous systematic reviews were hand-searched.
Moreover, the pharmaceutical companies marketing antidepressants, experts in this field and
trial authors were contacted for additional unpublished data.
Types of studies and interventions
We included randomized double-blind comparisons of antidepressants as monotherapy versus
placebo in the treatment of panic disorder. For trials that had a crossover design, only results
from the first randomized period were considered.
Types of participants
Participants were in- and out-patients aged 18 years or older of both sexes, with a primary
diagnosis of panic disorder with or without agoraphobia, diagnosed according to the criteria
described in the Diagnostic and Statistical Manual of Mental Disorders (DSM) [8] and Inter-
national Classification of Disease (ICD) [9], or according to any other clinical or standardized
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criteria adopted by the study authors. In case study eligibility focused on agoraphobia, rather
than panic disorder, studies were to be included if operationally diagnosed according to the
above-named criteria and when it could be safely assumed that at least 30% of the participants
were suffering from panic disorder as defined by the above criteria. We included participants
with a concurrent secondary diagnosis of another psychiatric disorder. We excluded partici-
pants with a concurrent primary diagnosis of Axis I or II disorders and participants with a seri-
ous concomitant comorbid physical disorder.
Data extraction
Two reviewers (IB and AB) independently extracted data from the included studies, and any
disagreement was discussed with a third member of the review team (CB).
For the purposes of the analysis reported here, the following two outcomes were extracted:
(a) efficacy, measured as number of patients responding to treatment as defined by the original
investigators; (b) adverse events, measured as proportion of patients complaining with any
adverse events.
Additionally, the following information was collected using an electronic spreadsheet: year
of publication, type of antidepressant, sample size, inclusion of elderly participants, setting of
intervention, diagnostic criteria, baseline number of panic attacks per week (as a proxy of ill-
ness severity), dose and probability of receiving placebo, rated according to Papakostas and
colleagues [10]. Mean doses were converted into multiples of the defined daily dosage (DDD)
for each drug by dividing the prescribed daily dosage (PDD) by the DDD (PDD/DDD). This
measure is the international unit of drug use approved by the World Health Organisation for
drug use studies [11,12].
Statistical analysis
Initially we investigated whether the proportion of patients experiencing adverse events signif-
icantly related to the overall efficacy of antidepressants. A meta-regression analysis was carried
out with the metareg command in STATA, which performs standard random-effects meta-
regression using aggregate-level data. Analyses were adjusted for the following variables: sam-
ple size, year of publication, type of antidepressant (SSRI versus any other), antidepressant
dose (PDD/DDD), probability of receiving placebo (high versus low), outpatients (yes = 1,
no = 0), elderly patients (yes = 1, no = 0), severity at baseline (yes = 1, no = 0) (S1 Table).
As second analytical step, the Baron and Kenny mediational model was applied to investigate
whether adverse events mediated the relationship between antidepressant treatment and effi-
cacy [13,14]. These analyses were performed at the study arm level. Therefore, in case of multi-
arm trials, each arm was considered separately. We reshaped the database from a wide format,
where rows identified comparisons, to a long format, where rows identified treatment arms (S2
Table). This allowed us to define the three variables of the Baron and Kenny approach: antide-
pressants treatment (predictor variable); responders to treatment (outcome variable); individu-
als with adverse events (mediator variable). According to Baron and Kenny, a mediating role of
a variable exists when four conditions are met: (i) the predictor variable must be significantly
related to the outcome variable; (ii) the hypothesized mediator must be significantly related to
the predictor variable; (iii) the mediator must be significantly related to the outcome; and (iv)
the relationship between the predictor and the outcome must be attenuated when controlling
for the mediator [13]. When predictor remains significant when the mediator is controlled for,
mediation is deemed to be partial. When controlling for the mediator renders the relationship
between predictor and outcome non-significant, mediation is deemed complete.
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A graphical representation of the model applied to antidepressant trials is presented in
Fig 1.
In model 1 we tested the relationship between antidepressant treatment and treatment
response. In model 2 we tested the relationship between antidepressant treatment and adverse
events. In model 3 we tested the relationship between adverse events and treatment response.
In model 4 we tested the effect of antidepressant treatment and adverse effects on treatment
response. Statistical significance was set at p< 0.05. Mediation was assessed by changes in sta-
tistical significance and in the magnitude of correlation coefficients (ß coefficient) between the
pathways 1 and 4. To adjust for possible confounding, the four regression analyses included
the following variables: sample size, year of publication, probability of receiving placebo, base-
line severity, outpatients, elderly patients. A nonparametric bootstrap method of statistical
accuracy was used in the four models of linear regression analyses, assuming that the observed
distribution of the present sample was a good estimate of the true population distribution [15].
All calculations were performed with Stata13 (STATA Corp, College Station, TX, USA).
Results
Characteristics of included studies
Of the original 41 randomised controlled trials included in the Cochrane review, 11 were
excluded because they did not report data on treatment response, and other 16 were excluded
Fig 1. Baron and Kenny mediational model. The model shows both the direct and the mediated pathways by which antidepressants treatment
influences efficacy. The mediated pathway investigates the potential mediational role of adverse events in the relationship between antidepressant
treatment and the number of responders at endpoint.
https://doi.org/10.1371/journal.pone.0178617.g001
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because they did not report the number of subjects experiencing adverse effects, leaving 14
studies for the present analysis [16–29]. The study selection process is shown in Fig 2.
Overall, 18 comparisons and 38 treatment arms were considered. The following com-
pounds were investigated in the included studies: imipramine (one study), paroxetine (5 stud-
ies), sertraline (3 studies), fluoxetine (one study), fluvoxamine (2 studies), citalopram (one
study), escitalopram (one study) and venlafaxine (4 studies). The main characteristics of
included studies are shown in Table 1. All studies were double-blind.
Univariate and multivariable meta-regression analysis
Fig 3 shows that in univariate analysis the RR for efficacy was not associated with the fre-
quency of antidepressant (Spearman rho -0.003, p = 0.990) and placebo (Spearman rho
-0.028, p = 0.904) adverse events.
Fig 2. PRISMA flow diagram.
https://doi.org/10.1371/journal.pone.0178617.g002
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Multivariable meta-regression analysis showed that, after adjustment for potential con-
founding variables, the RR for efficacy was not associated with the frequency of antidepressant
(coefficient -1.752, 95% CI -4.820 to 1.316, p = 0.229) and placebo (coefficient 1.401, 95% CI
-1.656 to 4.459, p = 0.327) adverse events (Table 2).
Mediational analyses
Table 3 presents the results of the Baron and Kenny approach. Model 1 tested the relationship
between antidepressants treatment and efficacy measured as treatment response. In this
model, antidepressants treatment was significantly associated with better treatment response
(ß = 0.127, 95% CI 0.04 to 0.21, p = 0.003).
Fig 3. Adverse events and response. Risk >1 favours antidepressants over placebo.
https://doi.org/10.1371/journal.pone.0178617.g003
Table 2. Meta-regression.
Independent variables Dependent variable: relative risk AD versus placebo (RR>1 favors AD)
Coefficient 95% Confidence interval P value
Sample size (continuous variable) 0.001 -0.002, 0.004 0.379
Year of study publication (continuous variable) 0.026 -0.026, 0.078 0.285
SSRI (yes = 1, no = 0) 0.379 -0.170, 0.928 0.153
Dose (PDD/DDD) (continuous variable) 0.021 -0.398, 0.440 0.912
Probability of receiving placebo (high = 1, low = 0) 0.084 -0.282, 0.449 0.617
Outpatients (yes = 1, no = 0) -0.088 -0.629, 0.453 0.721
Elderly patients (yes = 1, no = 0) -0.277 -0.788, 0.234 0.251
Severity at baseline (high = 1, low = 0) 0.223 -0.353, 0.799 0.404
AD adverse effects (continuous variable) -1.752 -4.820, 1.316 0.229
PLO adverse effects (continuous variable) 1.401 -1.656, 4.459 0.327
Constant term -51.304 -154.614, 52.006 0.290
https://doi.org/10.1371/journal.pone.0178617.t002
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Model 2 tested the relationship between antidepressants treatment and adverse events. In
this model, antidepressants treatment was not significantly associated with higher rates of sub-
jects with adverse events (ß = 0.094, 95% CI -0.05 to 0.24, p = 0.221).
Model 3 tested the relationship between adverse events and treatment response. In this
model, adverse events were inversely associated with treatment response (ß = -0.035, 95% CI
-0.06 to -0.05, p = 0.022).
Finally, model 4 tested the combined effect of antidepressants treatment and adverse effects
on treatment response. When adverse events were added to model 1, the relationship between
antidepressants treatment and treatment response was still statistically significant (ß = 0.122,
95% CI = 0.01 to 0.23, p = 0.039), although the effect was slightly attenuated, as can be inferred
from the magnitude of the coefficient.
Discussion
To our knowledge, this is the first study that formally investigated the potential role of adverse
events as mediators of treatment effect in antidepressant clinical trials conducted in individu-
als with panic disorder. We did not find evidence that the effects of antidepressants are medi-
ated by the perception of adverse events.
Our results do not confirm the findings of Greenberg and colleagues [1], who suggested
that, in patients with depressive disorder, post-treatment efficacy ratings were inflated by the
breaking of blind as a consequence of experiencing adverse events. However, the association
between adverse events and improvement reported in the Greenberg et al. meta-analysis was
based on four clinical trials only. Additionally, they did not carry out a mediational analysis. In
our analysis the approach described by Baron and Kenny was applied, in order to disentangle
the potential intermediate role of adverse events as mediators of the relationship between anti-
depressant treatment and efficacy in individuals with panic disorder. Our findings are consis-
tent with a recent work carried out by Barth and colleagues, who investigated the possible
mediational role of adverse events in explaining the efficacy of SSRIs in the treatment for
major depression. They similarly found no evidence for a mediational role of adverse events
[2].
Strengths and limitations
Strengths of this study include the following. Data were extracted from an ongoing Cochrane
systematic review, which employed a comprehensive search without language restrictions, and
included unpublished studies. Standard Cochrane methodology was applied throughout the
steps of study selection, data handling and analysis [30]. Although we cannot rule out an even
Table 3. Baron and Kenny mediational model.
MODEL INDEPENDENT
VARIABLE
DEPENDENT VARIABLE ADJUSTED FOR β coefficient
(95% CI)
P
value
MODEL
1
Treatment with
antidepressants
EFFICACY: NUMBER OF
RESPONDERS AT ENDPOINT
Year of publication, probability of receiving placebo,
baseline severity, sample size, outpatients, elderly
patients
0.127 (0.04,
0.21)
0.003
MODEL
2
Treatment with
antidepressants
Number of patients with adverse
events
0.094 (-0.05,
0.24)
0.221
MODEL
3
Number of patients with
adverse events
EFFICACY: NUMBER OF
RESPONDERS AT ENDPOINT
-0.035 (-0.06,
-0.05)
0.022
MODEL
4
Treatment with
antidepressants
EFFICACY: NUMBER OF
RESPONDERS AT ENDPOINT
Same variables as in Model 1, plus number of
patients with adverse events
0.122 (0.01,
0.23)
0.039
https://doi.org/10.1371/journal.pone.0178617.t003
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slight effect from unobserved covariates, another strength is that all analyses have been
adjusted for a number of study level confounders.
However, a number of limitations should be acknowledged. First, it was impossible to
investigate the breaking of blind directly, as the majority of the included clinical trials did not
assess this aspect. A second limitation is that only 14 trials out of the 41 potentially relevant
studies reported data on the number of participants experiencing adverse events. This is a
major issue not only because the analysis might have been more powerful statistically, but also
because it is difficult to speculate on whether lack of reporting happened by chance or rather it
may reflect some kind of reporting bias. Another limitation is that the meta-regression analysis
may suffer from low statistical power. Finally, study quality was not used as a confounding var-
iable as the Cochrane risk of bias tool is considered a qualitative and not quantitative tool [30].
Study implications
The finding that the drug-placebo differences are not due to the breaking of blind, as there was
no relationship with the perception of adverse events, is of paramount relevance clinically and
methodologically. Clinically, it implies that the moderate therapeutic effect of antidepressants
in individuals with panic disorder is not an artefact, therefore reflecting a genuine effect that
doctors can expect to replicate under real-world conditions. Methodologically, it implies that
double-blind placebo-controlled antidepressant trials are not biased by the differential emerg-
ing of adverse effects in those allocated to the active and control condition, at least in patients
with panic disorders.
In terms of implications for research, we argue that strategies to check blindness in future
clinical trials should always be employed. This could be achieved by using tools like the one
developed by Even and colleagues, who devised a short seven-point checklist to evaluate the
degree to which supposedly blind trials are protected from blindness penetration [31]. We also
argue that regulatory authorities should compulsory require the routine use of such instru-
ments in clinical trials conducted for regulatory purposes. In fact, any positive changes in
terms of trial design, analysis and reporting are likely to be achieved only if they are a require-
ment of new legislation [32,33]. Similarly, journals editors should no longer accept for publica-
tion trials reports that do not include this information.
A different and more radical strategy to overcome this issue would be to avoid placebo-con-
trolled antidepressant trials and require active-control trials in the evaluation of newer antide-
pressants. In comparative head-to-head trials it is expected that adverse events similarly occur
in both treatment arms, with a substantially lower risk of breaking the blind. This seems rea-
sonable in panic disorder, as effective drugs treatments are available in this condition to be
used as reference standards [7,34,35]. Regulatory authorities may require active-control supe-
riority clinical trials to generate evidence of superiority between competing treatments
[36,33,32,37].
In summary, this analysis does not support the hypothesis that the perception of adverse
events in placebo-controlled antidepressant clinical trials may induce patients to conclude that
they have been randomized to the active arm of the trial, leading to the breaking of blind and
to an artificial inflation of the efficacy measures.
Supporting information
S1 Table. Dataset antidepressants placebo for metaregression analysis.
(XLS)
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